샘플 요청 목록

 카트 문의
시장보고서
상품코드
1751231

철제 정맥주사 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 용도별, 지역별, 부문 예측(2025-2030년)

Intravenous Iron Drugs Market Size, Share, & Trends Analysis Report By Product (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose), By Application (Chronic Kidney Disease), By Region, And Segment Forecasts, 2025 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

철제 정맥주사 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 리포트에 따르면 세계의 철제 정맥주사 시장 규모는 2025-2030년에 CAGR 9.1%로 확대하며, 2030년에는 56억 2,000만 달러에 달할 전망입니다.

예측 기간 중 업계의 경쟁은 더 높은 수준으로 유지될 것으로 예측됩니다. 이 시장은 세계 기업이 매출 점유율의 대부분을 차지하고 있습니다. 또한 성장 기회는 새로운 기업을 끌어들이고 있으며, 경쟁사들 간의 적대적 관계를 더욱 강화시키고 있습니다. 시장은 세분화되어 있으며, 주요 기업은 더 큰 점유율을 확보하기 위해 전략적 제휴, 인수, 신약 출시 등 광범위한 성장 전략을 채택하고 있습니다.

감염으로 인한 높은 질병 부담은 영양실조와 함께 이 지역 소아 빈혈의 주요 원인 중 하나입니다. 신종 코로나바이러스의 대유행은 중증 환자의 빈혈을 증가시키고, 경우에 따라서는 저산소증을 유발하기도 합니다. 이로 인해 전 세계에서 빈혈 치료용 철분제에 대한 수요가 더욱 증가하고 있습니다.

빈혈 유병률 증가는 다양한 부인과 질환 및 소화기 질환에 기인하며, 정맥내 치료의 세계 보급을 촉진하고 있습니다. 예를 들어 빈혈의 전체 유병률은 비임신 여성의 경우 29.6%, 같은 연령대의 임산부의 경우 36.5%에 달할 전망입니다. 헬스케어 예산 증가와 투자 증가로 인해 시장은 예측 기간 중 크게 성장할 것으로 예측됩니다.

경구용 철분제의 단점인 복통, 변비, 식욕부진, 메스꺼움, 구토 등 소화기 계통의 문제는 환자들이 정맥주사제를 선호하는 이유입니다. 철분제를 정맥 주사하면 체내 철분 흡수를 촉진하고 적혈구 조혈 자극인자(ESA)의 작용을 촉진하여 빈혈 상태를 개선하는 것으로 나타났습니다. 이 외에도 심장 건강 유지, 투석 환자, 특히 혈액투석 환자도 사용할 수 있다는 장점이 있습니다.

정맥내 철분제 시장 보고서 하이라이트

  • 카르복시 말토오스 철분은 2024년, 그 용도 증가, 부작용이 적고 우수한 성능, 비용 절감과 함께 2024년 철분제 정맥주사 산업을 지배했습니다.
  • 자당 철은 2024년 시장에서 큰 점유율을 차지했습니다. 심각한 알레르기 반응의 낮은 발생률은 이러한 약물의 채택률을 높이고 있습니다.
  • CKD 및 CKD와 관련된 철분 결핍성 빈혈 환자 증가로 인해 만성 신장질환 부문이 2024년 가장 큰 점유율을 차지했습니다.
  • 북미는 2024년 점적투여 의약품에 대한 높은 수요와 소화기 질환, 암, CKD 유병률 증가로 인해 가장 규모가 큰 지역 점유율을 차지했습니다.
  • 아시아태평양은 미충족 수요 증가, 의료비 증가, 기존 세계 기업의 현지 진출로 인해 예측 기간 중 가장 빠르게 성장할 것으로 예측됩니다.

목차

제1장 조사 방법과 범위

제2장 개요

제3장 철제 정맥주사 시장의 변수, 동향, 범위

  • 시장 계통 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 비즈니스 환경 분석
    • 업계 분석 - Porter's Five Forces 분석
    • PESTLE 분석
    • 파이프라인 분석
    • 특허 만료 분석
    • 가격 분석

제4장 철제 정맥주사 시장 : 제품별 비즈니스 분석

  • 제품별 시장 점유율, 2024년과 2030년
  • 제품별 부문 대시보드
  • 시장 규모, 예측, 동향 분석(제품별, 2018-2030년)
  • 철 덱스트란
  • 철 수크로스
  • Ferric Carboxymaltose
  • 기타

제5장 철제 정맥주사 시장 : 용도별 비즈니스 분석

  • 용도별 시장 점유율, 2024년 및 2030년
  • 용도별 부문 대시보드
  • 시장 규모, 예측, 동향 분석(용도별, 2018-2030년)
  • 만성 신장병
  • 염증성장질환
  • 암
  • 기타 질병

제6장 철제 정맥주사 시장 : 지역별 추정·동향 분석

  • 지역별 시장 점유율 분석, 2024년 및 2030년
  • 지역별 시장 대시보드
  • 시장 규모와 예측 동향 분석, 2018-2030년
  • 북미
    • 국가별, 2018-2030년
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 덴마크
    • 스웨덴
    • 노르웨이
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 한국
    • 태국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트
    • 쿠웨이트

제7장 경쟁 구도

  • 참가자 개요
  • 기업의 시장 현황 분석
  • 기업 분류
  • 전략 지도제작
  • 기업 개요/상장기업
    • AbbVie Inc.
    • AMAG Pharmaceuticals(Covis Pharma)
    • Daiichi Sankyo Company, Ltd.
    • Sanofi
    • Vifor Pharma Management Ltd.(CSL)
    • PHARMACOSMOS A/S
    • Zydus Group
    • Rockwell Medical, Inc.
KSA 25.06.26

Intravenous Iron Drugs Market Growth & Trends:

The global intravenous iron drugs market size is expected to reach USD 5.62 billion by 2030, expanding at a CAGR of 9.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Industry rivalry is expected to remain at a higher level over the forecast period. The market is dominated by global players accounting for most of the revenue share. Moreover, growing opportunities attract new players, which further augments the competitive rivalry. The market is fragmented and major players are involved in adopting extensive growth strategies such as entering strategic alliances, acquisitions, and new drug launches to capture a larger share.

The high disease burden of infectious diseases, coupled with poor nutrition, is one of the major causes of anemia among children in this region. The novel coronavirus pandemic has also increased anemia in severely affected patients, causing hypoxia in some cases. This has further increased the demand for intravenous iron drugs for the treatment of anemia across the globe.

The increase in the prevalence of anemia can also be attributed to various gynecological and gastrointestinal disorders, facilitating an increasing uptake of IV treatment globally. For instance, the overall prevalence of anemia is 29.6% in nonpregnant women and 36.5% in pregnant women of the same age group. With growing healthcare budgets and increasing investment, the market is anticipated to grow significantly during the forecast period.

Drawbacks of oral iron drugs such as digestive problems such as stomach aches, constipation, loss of appetite, nausea, and vomiting are reasons for patients to prefer intravenous drugs. The use of intravenous iron drugs has been shown to bring about increased iron adoption by the body, facilitating Erythropoiesis-stimulating Agents (ESAs) to function in an enhanced manner to improve the anemic condition. Other advantages are the preservation of heart health and the ability to be used by dialysis patients, especially those undergoing hemodialysis.

Intravenous Iron Drugs Market Report Highlights:

  • Ferric carboxymaltose dominated the intravenous iron drugs industry in 2024 due to its increasing application, superior performance coupled with fewer adverse effects, and reduced cost.
  • Iron sucrose held a significant share of the market in 2024. A low rate of severe allergic reactions has increased the adoption rate of these drugs.
  • The chronic kidney disease segment held the largest share in 2024, due to the increasing prevalence of CKD and CKD-associated iron deficiency anemia cases.
  • North America held the largest regional share in 2024 due to the high demand for intravenous drugs and the increasing prevalence of GI disorders, cancer, and CKD.
  • Asia Pacific is estimated to exhibit the fastest growth over the forecast period attributed to growing unmet patient needs, increasing healthcare expenditure, and the local presence of established global players.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Intravenous Iron Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Intravenous Iron Drugs Market: Product Business Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Product Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Iron Dextran
    • 4.4.1. Iron Dextran Market, 2018 - 2030 (USD Million)
  • 4.5. Iron Sucrose
    • 4.5.1. Iron Sucrose Market, 2018 - 2030 (USD Million)
  • 4.6. Ferric Carboxymaltose
    • 4.6.1. Ferric Carboxymaltose Market, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Intravenous Iron Drugs Market: Application Business Analysis

  • 5.1. Application Market Share, 2024 & 2030
  • 5.2. Application Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Chronic Kidney Disease
    • 5.4.1. Chronic Kidney Diseases Market, 2018 - 2030 (USD Million)
  • 5.5. Inflammatory Bowel Disease
    • 5.5.1. Inflammatory Bowel Disease Market, 2018 - 2030 (USD Million)
  • 5.6. Cancer
    • 5.6.1. Cancer Market, 2018 - 2030 (USD Million)
  • 5.7. Other Diseases
    • 5.7.1. Other Diseases Market, 2018 - 2030 (USD Million)

Chapter 6. Intravenous Iron Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 6.4. North America
    • 6.4.1. North America Intravenous Iron Drugs Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. UK Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Intravenous Iron Drugs Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Intravenous Iron Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. AbbVie Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. AMAG Pharmaceuticals (Covis Pharma)
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Daiichi Sankyo Company, Ltd.
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Sanofi
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Vifor Pharma Management Ltd. (CSL)
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. PHARMACOSMOS A/S
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Zydus Group
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Rockwell Medical, Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제